The Medicare Current Beneficiary-Survey (MCBS) is a powerful tool for analyzing enrollees\' access to medical care ([@b1-hcfr-17-4-213]). Based on a stratified random sample, we can derive information about the health care use, expenditure, and financing of Medicare\'s 36 million enrollees. We can also learn about those enrollees\' health status, living arrangements, and access to and satisfaction with care.

In the charts that follow, we have presented some findings on variations in the use of prescribed medicines by Medicare fee-for-service (FFS) and health maintenance organization (HMO) enrollees.
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-   HMO and FFS beneficiaries have roughly the same user rates.
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-   HMO enrollees pay slightly more than one-half that of their FFS counterparts on out-of-pocket prescription drug expenditures.

###### Generic Versus Brand-Name Drug Usage Among FFS and HMO Beneficiaries

  Drug         FFS Mentions   Drug            HMO Mentions
  ------------ -------------- --------------- --------------
  Lanoxin      11,040,029     FUROSEMIDE      765,020
  Cardizem     7,279,562      Lanoxin         738,471
  Procardia    6,848,458      Vasotec         580,145
  Zantac       6,775,104      Cardizem        545,495
  FUROSEMIDE   6,190,546      HCTZ\*\*        496,224
  Lasix        6,000,161      Procardia       479,228
  Vasotec      5,992,800      Premarin        413,688
  Synthroid    5,697,207      Synthroid       402,307
  Capoten      5,500,437      ISOSORBIDE DN   401,875
  Premarin     5,131,864      Ventolin        386,878

NOTES: HCTZ is Hydrochlorothiazide. Includes all beneficiaries who did not receive care from both FFS and Medicare HMOs during the year. Dual eligibles and those in institutions have been excluded from the analysis. Numbers may not add to totals due to rounding. Figures do not account for non-respondents. Drug names in capitals indicate generic. One mention equates to one container of a given medication. Does not include any drugs classified as "untranslatable" due to unrecognizable spellings.

SOURCE: Health Care Financing Administration, Office of the Actuary: Medicare Current Beneficiary Survey.

-   Of the top ten prescribed medications within FFS and HMO, FFS beneficiaries reported only one generic medicine, while their HMO counterparts reported three generics, including the most frequently cited drug.

-   The top ten FFS drugs represent 17.2 percent of all FFS mentions and 17.9 percent of FFS drug expenditures. The top ten HMO drugs represent 19.9 percent of all mentions and 17.3 percent of expenditures.
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